Inhibition of the classical complement pathway with a therapeutically relevant C1q function-blocking antibody and genetic ablation of complement receptor CR3, a gene almost exclusively expressed by microglia in the brain, both reduce early loss of corticostriatal synapses in HD mouse models. The gene discussed is CRIPTO3; the disease is Huntington disease.